跳轉至內容
Merck
全部照片(2)

Key Documents

T9262

Sigma-Aldrich

他莫昔芬 柠檬酸盐

≥99% (TLC), powder, PKC inhibitor

同義詞:

(Z)-1-(对二甲基氨基乙氧基苯基)-1,2-二苯基-1-丁烯

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C26H29NO · C6H8O7
CAS號碼:
分子量::
563.64
EC號碼:
MDL號碼:
分類程式碼代碼:
12161501
PubChem物質ID:
NACRES:
NA.77

product name

他莫昔芬 柠檬酸盐, ≥99%

品質等級

化驗

≥99%

溶解度

methanol: soluble 50 mg/mL, clear, colorless

起源

AstraZeneca

儲存溫度

2-8°C

SMILES 字串

OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

InChI 密鑰

FQZYTYWMLGAPFJ-OQKDUQJOSA-N

尋找類似的產品? 前往 產品比較指南

應用

他莫昔芬已被用于分析其对人乳腺癌细胞辐射敏感性和类固醇受体含量的影响 。也用于研究雌性大鼠肝组织中三酰甘油的蓄积 。此外,有研究报道环境磁场可阻断他莫昔芬在人乳腺癌细胞中的抗增殖功能

生化/生理作用

蛋白激酶 C 抑制剂。诱发人类恶性神经胶质瘤细胞系的细胞凋亡。他莫昔芬及其代谢产物 4-羟基他莫昔芬是选择性雌激素反应调节剂 (SERM),在乳腺中用作雌激素拮抗剂。阻止乳腺肿瘤细胞中雌二醇刺激的 VEGF 的产生。

特點和優勢

该化合物是受体分类及信号转导手册上核受体(类固醇)页面上的特色化合物。想要浏览手册的其他页面, 请单击此处
该化合物由 AstraZeneca 公司开发。若要浏览其他制药公司研发的化合物和批准的药物/候选药物列表,请单击此处
这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

準備報告

枸橼酸他莫昔芬盐溶于 50 mg/mL 甲醇,形成澄清、无色溶液。

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

J D Harland et al.
Bioelectromagnetics, 18(8), 555-562 (1997-01-01)
We have previously reported that environmental-level magnetic fields (1.2 microT [12 milligauss], 60 Hz) block the growth inhibition of the hormone melatonin (10(-9) M) on MCF-7 human breast cancer cells in vitro. We now report that the same 1.2 microT
Oddrun Anita Gudbrandsen et al.
Journal of lipid research, 47(10), 2223-2232 (2006-07-26)
Tamoxifen can induce hepatic steatosis in women. In this study, we wanted to elucidate the mechanism behind the tamoxifen-induced accumulation of triacylglycerol in liver in female rats, and we hoped to prevent this development by combination treatment with the modified
G H Paulsen et al.
Acta oncologica (Stockholm, Sweden), 35(8), 1011-1019 (1996-01-01)
Possible influences of tamoxifen and estradiol on in vitro radiation sensitivity and cellular receptor content after irradiation and/or tamoxifen treatment were studied in breast cancer cell lines; estrogen receptor (ER) and progesterone receptor (PgR) positive cell lines MCF-7 and MCF-7/TAM(R)-1
K I Pritchard
Journal of internal medicine, 274(2), 144-152 (2013-07-13)
Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer. It was used successfully without a known target for more than 50 years before Jensen described the oestrogen receptor (ER) in the 1960s. Subsequently, it
Kevin S Hughes et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2382-2387 (2013-05-22)
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務